Baum Douglas R 5
5 · QSAM Biosciences, Inc. · Filed Feb 15, 2022
Insider Transaction Report
Form 5
Baum Douglas R
DirectorCEO & Director
Transactions
- Other
Common Stock
2021-12-06+10,093,800→ 10,093,800 total - Award
Options to buy common Stock
2020-01-14+8,000→ 8,000 totalExercise: $0.50Exp: 2025-01-14→ Common Stock (8,000 underlying) - Other
Series E-1 Preferred Stock
2021-12-06−2,975→ 0 total - Purchase
Series B Preferred Stock
2021-01-22$3000.00/sh+3$9,000→ 3 total - Award
Series E-1 Preferred Stock
2020-12-30+2,975→ 0 totalExercise: $0.00→ Common Stock (2,975,000 underlying) - Award
Options to buy common Stock
2021-08-24+125,000→ 125,000 totalExercise: $0.36Exp: 2031-08-23→ Common Stock (125,000 underlying)
Footnotes (4)
- [F1]Pursuant to reclassification exempt under Rule 16b-7, each share of Series E-1 Preferred Stock was reclassified into and exchanged for shares of Common Stock of the Issuer under the terms of Exchange Agreement and Plan of Reorganization as filed with the SEC.
- [F2]Series E-1 preferred stock was convertible at any time at the discretion of the holder at a ratio of 1000 shares of common stock per Series E-1 preferred stock.
- [F3]The options vests annually in two equal installments beginning on 1/14/2021.
- [F4]The option vestssemi-annually in two equal installments beginning on 02/24/2022.